Abstract:Junling Li Wei Li Xiaojian Dai Dafang Zhong Yaping Ding Xiaoyan Chen 1College of Sciences, Shanghai University, Shanghai, People’s Republic of China; 2Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People’s Republic of China Background and objective: Paclitaxel protein-bound particles for injectable suspension (nab-paclitaxel) showed many advantages in safety, effectiveness, and convenience. Different from conventional formulations, the bioequivalence evaluation of nab-paclitaxel formulations requires to determine the total amount of paclitaxel in plasma and the unbound paclitaxel to reflect their in vivo disposition. This study aimed to develop an analytical method to quantify the total and unbound paclitaxel in plasma and evaluate the bioequivalence of two formulations of nab-paclitaxel in patients with breast cancer. Materials and methods: An open-label, randomized, two-period crossover study was completed among 24 Chinese patients with breast cancer. The patients were randomized to receive either the test formulation on cycle 1 day 1 and after 21 days in cycle 2 day 1 by the reference formulation (Abraxane®), or vice versa. Rapid equilibrium dialysis was adopted to separate the unbound paclitaxel in human plasma. Total and unbound paclitaxel concentrations were measured by the validated liquid chromatography–tandem mass spectrometry methods over the range of 5.00–15,000 and 0.200–200 ng/mL, respectively. The bioequivalence of the test formulation to the reference formulation was assessed using the Food and Drug Administration and European Medicines Agency guidelines. Results: All the 90% confidence intervals (CIs) of the geometric mean ratios fell within the predetermined acceptance range. The 90% CIs for the area under the concentration–time curve (AUC) from 0 h to 72 h (AUC0–t), AUC from time zero to infinity (AUC0–∞), and peak plasma concentrations (Cmax) for total paclitaxel were 92.03%–98.05%, 91.98%–99.37%, and 91.37%–99.36%, respectively. The 90% CIs of AUC0–t, AUC0–∞, and Cmax for unbound paclitaxel were 86.77%–97.88%, 86.81%–97.88%, and 87.70%–98.86%, respectively. Conclusion: Bioequivalence between the two nab-paclitaxel formulations was confirmed for total and unbound paclitaxel at the studied dose regimen.

The Binding Affinity of Human Serum Albumin and Paclitaxel Through Mmpbsa Based on Docked Complex

Effect of Solvent Water Molecules on Human Serum Albumin Complex Docked Paclitaxel by MM-PBSA Method

Interactions of Self-Assembled Bletilla S triata Polysaccharide Nanoparticles with Bovine Serum Albumin and Biodistribution of Its Docetaxel-Loaded Nanoparticles.

Interactions of human serum albumin with phosphate and Tris buffers: impact on paclitaxel binding and nanoparticles self-assembly

Interaction of the docetaxel with human serum albumin using optical spectroscopy methods

Surface-enhanced Raman spectroscopy study of the interaction of antitumoral drug Paclitaxel with human serum albumin

Paclitaxel Loaded Human Serum Albumin Nanoparticles Stabilized with Intermolecular Disulfide Bonds

Quantification of paclitaxel in rat plasma by LC-MS/MS and pharmacokinetics of paclitaxel thermosensi-tive liposomes in rats

Spectroscopic Investigation on the Binding of Antineoplastic Drug Oxaliplatin to Human Serum Albumin and Molecular Modeling

Drug-binding albumins forming stabilized nanoparticles for efficient anticancer therapy.

Studies on the Binding of A Carditionic Agent to Human Serum Albumin by Two-Dimensional Correlation Fluorescence Spectroscopy and Molecular Modeling

Preparation of stable and monodisperse paclitaxel-loaded bovine serum albumin nanoparticles via intermolecular disulfide crosslinking

Eftects Of Lipid Chain Unsaturation And Headgroup Type On Molecular Interactions Between Paclitaxel And Phospholipid Within Model Biomembrane

Analysis on the interaction and binding properties of daphnoretin and human serum albumin in the presence of cisplatin: multi-spectroscopic methods and docking simulation

Molecular Dynamics Simulation and Density Functional Theory Studies on the Active Pocket for the Binding of Paclitaxel to Tubulin

Uncovering the Molecular and Physiological Processes of Anticancer Leads Binding Human Serum Albumin: A Physical Insight into Drug Efficacy

Dddt_a_200679 1739..1749

Thermal effects and drugs competition on the palmitate binding capacity of human serum albumin

Study on Paclitaxel-Human Serum Albumin Interaction by Capillary Zone Electrophoresis

Biological Evaluation of Peg Modified Nanosuspensions Based on Human Serum Albumin for Tumor Targeted Delivery of Paclitaxel

Comparison the pharmacokinetics of nanoparticle albumin bound paclitaxel and solvent based paclitaxel in breast cancer patients